Aethlon Medical Greenlights Australian Trial Cohort 2 and Raises $4.5M for Hemopurifier
By ATTN Desk · Editorial oversight: Sean Han
Aethlon Medical Inc: Company Overview
Aethlon Medical Inc (NASDAQ: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Founded in 1999, the company employs between 11 and 50 staff members focused on developing the Aethlon Hemopurifier®, an extracorporeal immunotherapeutic device designed to remove cancer-promoting exosomes and enveloped viruses from circulation. The U.S. Food and Drug Administration (FDA) has designated the Hemopurifier® as a Breakthrough Device for both advanced or metastatic cancer unresponsive to standard therapies and life-threatening viruses lacking approved treatments.
Corporate Structure and Stock Profile
Aethlon Medical operates under an open Investigational Device Exemption (IDE) for oncology and infectious disease indications. Key corporate details include:
- Headquarters: San Diego, California
- Industry: Medical Equipment Manufacturing
- Nasdaq Ticker: AEMD
- Employee Count: 11–50
As of September 11, 2025, the stock traded at $0.6650, up 2.12% on a volume of 134,242 shares (average volume: 41,709). Ownership disclosures filed on September 10, 2025, indicated that certain investors hold 576,603 shares, representing 7.7% of outstanding common stock, all under shared voting power.
| Metric | Value |
|---|---|
| Price (Sep 11, 2025) | $0.6650 |
| Market Capitalization | $4.13 million |
| Total Cash (mrq) | $3.77 million |
| Total Debt/Equity (mrq) | 20.06% |
| Net Income (TTM) | –$12.58 million |
| Diluted EPS (TTM) | –6.67 |
| Beta (5Y Monthly) | 1.72 |
| 52-Week Range | $1.08 – $8.48 |
Hemopurifier by Harper Sunday
Recent Developments and Regulatory Milestones
On July 15, 2025, Aethlon announced that its independent Data Safety Monitoring Board (DSMB) completed a scheduled safety review of the first cohort in the Australian oncology trial (AEMD-2022-06) and recommended advancing to the next patient cohort without modification. No treatment-related serious adverse events or dose-limiting toxicities were reported among the initial three participants.
During the quarter ended August 13, 2025, the company reported:
- Completion of the first Australian cohort with no device deficiencies.
- Formal approval from India’s Central Drugs Standard Control Organization to initiate an oncology trial, although resources remain focused on Australia.
- A 32% reduction in operating expenses through payroll and consulting cost savings.
- Presentation of preclinical data regarding the Hemopurifier®’s potential application in long COVID.
- A 43% cash tax rebate in Australia to partially offset research expenditures.
On September 5, 2025, Aethlon filed a prospectus (Rule 424(b)(4)) to offer up to 4,047,780 shares of common stock at $0.90 per share, pre-funded warrants for 952,220 shares, and warrants for an additional 5,000,000 shares. If fully subscribed, gross proceeds could reach approximately $4.5 million, subject to a 6.25% placement agent fee.
Financial and Strategic Analysis
Aethlon’s market capitalization stands at approximately $4.13 million, with an enterprise value near $940,650. The company has not yet generated revenue and reported a net loss of $12.58 million over the trailing twelve months, with a negative free cash flow of $5.09 million. As of the most recent quarter, total cash balances of $3.77 million provide a runway for ongoing clinical activities, though additional capital may be required to complete trials and support broader development programs.
Strategically, the Hemopurifier® benefits from its FDA Breakthrough Device designation and an open IDE, potentially expediting regulatory review. The focus on the Australian trial leverages tax rebates and cost advantages. Aethlon is also exploring applications beyond oncology, including treatment options for life-threatening viral infections and long COVID.
Market Position and Industry Context
Aethlon operates in the medical device segment of the biotechnology industry, targeting unmet needs in oncology and infectious disease. The Hemopurifier® competes with other immunotherapeutic platforms by offering a non-pharmacologic mechanism—extracorporeal removal of pathogenic targets. The device’s clinical validation and regulatory designations provide differentiation within a field that includes antibody therapies, small-molecule antivirals, and cellular immunotherapies. With a 52-week trading range of $1.08 to $8.48, the stock reflects a valuation driven by clinical progress rather than current commercial revenues.
tl;dr
The independent DSMB recommended on July 15, 2025, that Aethlon Medical proceed to cohort 2 of its Australian oncology trial, following a safety review of the first cohort. Cohort 2 enrollment is underway, and the company has achieved a reduction in operating expenses of 32%. On September 5, 2025, Aethlon launched a $4.5 million equity offering to fund clinical development. Key upcoming milestones include safety and feasibility data from cohort 2, the planned earnings report on November 12, 2025, and ongoing regulatory updates for global trial expansion.